Michael Schmitz
Stock Analyst at Guggenheim
(1.39)
# 2,517
Out of 4,433 analysts
11
Total ratings
60%
Success rate
5.12%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Upgrades: Buy | $40 | $32.68 | +22.40% | 1 | Nov 20, 2023 | |
| RVMD Revolution Medicines | Reiterates: Buy | $38 | $39.41 | -3.58% | 1 | Feb 28, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $3.90 | - | 1 | Jan 3, 2023 | |
| BPMC Blueprint Medicines | Maintains: Buy | $110 → $85 | $104.96 | -19.02% | 7 | Nov 2, 2022 | |
| NOVA Sunnova Energy International | Initiates: Buy | n/a | $4.20 | - | 1 | Jan 6, 2020 |
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $32.68
Upside: +22.40%
Revolution Medicines
Feb 28, 2023
Reiterates: Buy
Price Target: $38
Current: $39.41
Upside: -3.58%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.90
Upside: -
Blueprint Medicines
Nov 2, 2022
Maintains: Buy
Price Target: $110 → $85
Current: $104.96
Upside: -19.02%
Sunnova Energy International
Jan 6, 2020
Initiates: Buy
Price Target: n/a
Current: $4.20
Upside: -